BB-031 / BB-025
Acute Thrombotic Conditions (e.g., Acute Ischemic Stroke)
Pre-clinicalActive
Key Facts
Indication
Acute Thrombotic Conditions (e.g., Acute Ischemic Stroke)
Phase
Pre-clinical
Status
Active
Company
About Basking Biosciences
Basking Biosciences is pioneering a new approach to treating acute thrombosis by targeting von Willebrand Factor (vWF) with a short-acting, reversible RNA aptamer therapy. The company's platform combines BB-031, a vWF inhibitor, with BB-025, a specific reversal agent, designed to enable precise control during critical interventions like stroke. Led by an experienced team with deep expertise in thrombosis and drug development, Basking is advancing its lead program through clinical trials to address a significant unmet need in vascular emergencies. The company is privately held and pre-revenue, focusing on demonstrating the safety and efficacy of its novel therapeutic paradigm.
View full company profile